PsychRounds: The Psychiatry Podcast

Welcome to an introductory episode on anxiety disorders as requested by a long-time listener. References:https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/https://pmc.ncbi.nlm.nih.gov/articles/PMC5573565/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/175862/Nesse%20Anxiety%20Disorders%20in%20Evolutionary%20Perspective%202022.pdf?sequence=1

Join us as we talk about Loxapine, an older medication that’s stood the test of time and found a niche in psychiatric practice. This is a revision of an earlier episode, after Dr. Bradley Miller chatted with Dr. Jonathan Meyer at the 2025 APA Conference. Dr. Meyer joins us at the beginning to provide an addendum to the original episode.

Discover the intriguing world of Pregabalin, known as Lyrica, and how it stacks up against Gabapentin in psychiatric settings. The hosts delve into its unique mechanism of action and impressive absorption advantages. They explore its efficacy for generalized anxiety disorder and contrast its performance with venlafaxine. Tune in for insights on dosing, potential side effects, and concerns about misuse. With a look at its role in bipolar disorder and alcohol use, this discussion highlights essential considerations for prescribing.

Explore the intriguing rise of gabapentin, originally approved for seizures, now often used off-label in psychiatry. Delve into its contentious safety profile, revealing concerns about misuse and overdose risks, especially with opioids. Hear about its varied effectiveness in treating anxiety, alcohol use disorder, and even its limited role in bipolar disorder. The hosts break down the pharmacology behind this complex medication, discussing clinical implications and the evolving landscape of its use in mental health.

In this engaging discussion, Dr. Bruce Perry, a leading child psychiatrist and co-author of acclaimed books on trauma, shares insights about his Neurosequential Model of Therapeutics. He breaks down the complexities of trauma, contrasting 'big T' and 'little T' experiences, and emphasizes how these affect child development. Dr. Perry also delves into the significance of emotional regulation, the impact of modern lifestyles on community connections, and the therapeutic power of rhythm. His holistic approach underscores the necessity of tailored treatments for recovery.

Join Dr. Chris Aiken, Editor-in-Chief of the Carlat Psychiatry Report and Yale-trained psychiatrist, as he explores the intriguing spectrum of mood disorders. He discusses the distinction between bipolar disorder and manic-depressive illness, the impact of individual temperaments on treatment, and innovative non-pharmacological strategies. Dr. Aiken also delves into the potential of the keto diet and the role of nutrition in mental health. Plus, insights on sleep patterns and their effects on mood make for a compelling conversation!

Pramipexole, known for treating Parkinson's, is explored for its unexpected role in treatment-resistant depression. The discussion dives into its mood-enhancing effects and unique mechanisms tied to motivation. Safety concerns arise, particularly regarding side effects like impulse control issues. A revealing study highlights pramipexole's potential as an augmentation therapy for depression, showcasing significant symptom improvement. The conversation also emphasizes the risks and benefits of dopamine agonists, urging safe practices in patient management.

In this conversation, Dr. Charles Raison, a prominent psychiatrist and researcher, dives into the fascinating intersection of psychedelics and consciousness. He discusses innovative treatments for depression, including whole-body hyperthermia and Tibetan Buddhist practices like tummo. Raison examines the evolution of consciousness, the influence of technology on mental health, and how psychedelics can enhance neuroplasticity and memory. Listeners will discover the promising potential of integrating ancient practices with modern science.

Dr. Charles Raison, a renowned psychiatrist and professor, dives deep into the biological and evolutionary aspects of depression. He discusses the role of inflammation and the HPA axis in mood disorders. Raison highlights innovative treatments, including psychedelics, and the potential of precision medicine tailored to inflammation responses. The conversation also honors the late Dr. Vladimir Maletic, reflecting on his significant contributions to psychiatry. Listeners gain insights into major depressive disorder's complexities and emerging therapies like pramipexole.

Welcome Back! We have recently partnered with Psych Congress to bring our audience access to some of their leading speakers and educators, and today is the second installment of this endeavor, featuring Dr. Jonathan Meyer on the topic of Antipsychotic plasma level monitoring. Dr. Meyer has authored the handbook on this topic, along with the Lithium and Clozapine handbooks as well. You can find them here: https://www.amazon.com/s?k=jonathan+meyer&crid=3IARW0R4T9RGD&sprefix=jona%2Caps%2C369Psych Congress Discount Code: PSYCHROUNDSConference Website: https://www.hmpglobalevents.com/psych-congressSources:- https://www.cambridge.org/core/books/clinical-use-of-antipsychotic-plasma-levels/E7C0B6DBB4F6031F4D47935154CBEC8D